Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 12:00 ET | Source: Kailera Therapeutics, Inc.; Hengrui Pharma

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Hengrui Pharma & Kailera Therapeutics Present Additional Data from Phase 3 Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 at Obesity Week